SONX · Sonendo, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“There is a material uncertainty that raise substantial doubt about our ability to continue as a going concern and, therefore, that we may be unable to realize our assets and discharge our liabilities in the normal course of business.”View the 10-K filed Mar 26, 2025
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Nov 8, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SONX
this stock
Sonendo, Inc.
|
$235,071 | +83.3% | -24.3% | — | 0.0% |
|
ABT
Abbott Laboratories
|
$193.78B | -10.1% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -5.7% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -4.1% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$74.64B | -47.1% | +12.5% | 20.9 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -37 sh
- Top holder
- First Light Asset Managem…
Performance
Raw-price comparisons begin at the captured split on Nov 8, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SONX | -32.9% | +83.3% | -74.2% | -45.5% | +83.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -33.3% | +78.9% | -88.0% | -49.5% | +69.5% |